Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study
摘要:
Preliminary hit-to-lead optimization of a novel series of phenylsulfonyl hydrazide derivatives, which were derived from the high throughput screening hit compound 1 (IC50 = 5700 nM against PGE(2) production), for a potent suppressor of PGE(2) production is described. Subsequent optimization led to the identification of the potent lead compound 8n with IC50 values of 4.5 and 6.9 nM, respectively, against LPS-induced PGE(2) production and NO production in RAW 264.7 macrophage cells. In addition, 8n was about 30- and > 150-fold more potent against mPGES-1 enzyme in a cell-free assay (IC50 = 70 nM) than MK-886 and hit compound 1, respectively. Molecular docking suggests that compound 8n could inhibit PGE2 production by blocking the PGH(2) binding site of human mPGES-1 enzyme. (C) 2015 Elsevier Ltd. All rights reserved.
Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study
摘要:
Preliminary hit-to-lead optimization of a novel series of phenylsulfonyl hydrazide derivatives, which were derived from the high throughput screening hit compound 1 (IC50 = 5700 nM against PGE(2) production), for a potent suppressor of PGE(2) production is described. Subsequent optimization led to the identification of the potent lead compound 8n with IC50 values of 4.5 and 6.9 nM, respectively, against LPS-induced PGE(2) production and NO production in RAW 264.7 macrophage cells. In addition, 8n was about 30- and > 150-fold more potent against mPGES-1 enzyme in a cell-free assay (IC50 = 70 nM) than MK-886 and hit compound 1, respectively. Molecular docking suggests that compound 8n could inhibit PGE2 production by blocking the PGH(2) binding site of human mPGES-1 enzyme. (C) 2015 Elsevier Ltd. All rights reserved.
[EN] RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RHO KINASE
申请人:SURFACE LOGIX INC
公开号:WO2010104851A1
公开(公告)日:2010-09-16
The present invention relates to inhibitors of ROCK1 and ROCK2, which may be selective for ROCK2, and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and/or ROCK2. Also provided are treatments combining inhibitors of ROCK1 and/or ROCK2 with statins.
Hit-to-lead optimization of phenylsulfonyl hydrazides for a potent suppressor of PGE2 production: Synthesis, biological activity, and molecular docking study
作者:Minju Kim、Sunhoe Lee、Eun Beul Park、Kwang Jong Kim、Hwi Ho Lee、Ji-Sun Shin、Katrin Fischer、Andreas Koeberle、Oliver Werz、Kyung-Tae Lee、Jae Yeol Lee
DOI:10.1016/j.bmcl.2015.11.024
日期:2016.1
Preliminary hit-to-lead optimization of a novel series of phenylsulfonyl hydrazide derivatives, which were derived from the high throughput screening hit compound 1 (IC50 = 5700 nM against PGE(2) production), for a potent suppressor of PGE(2) production is described. Subsequent optimization led to the identification of the potent lead compound 8n with IC50 values of 4.5 and 6.9 nM, respectively, against LPS-induced PGE(2) production and NO production in RAW 264.7 macrophage cells. In addition, 8n was about 30- and > 150-fold more potent against mPGES-1 enzyme in a cell-free assay (IC50 = 70 nM) than MK-886 and hit compound 1, respectively. Molecular docking suggests that compound 8n could inhibit PGE2 production by blocking the PGH(2) binding site of human mPGES-1 enzyme. (C) 2015 Elsevier Ltd. All rights reserved.